<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordsOutput><serviceExecutionTime>333</serviceExecutionTime><Drug id="53738"><DrugName>lidocaine gel (ophthalmic formulation, ocular anesthesia), Akorn</DrugName><DrugNamesKey><Name id="42858844">Akten</Name><Name id="42749404">lidocaine</Name></DrugNamesKey><DrugSynonyms><Name><Value>lidocaine</Value><Types><Type>BANN</Type><Type>INN</Type></Types></Name><Name><Value>AK-1015</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>lidocaine gel (ophthalmic formulation, ocular anesthesia), Akorn</Value></Name><Name><Value>Akten</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>137-58-6</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="28817">Akorn Inc</CompanyOriginator><CompaniesPrimary><Company id="28817">Akorn Inc</Company></CompaniesPrimary><CrossReferences><SourceEntity id="28817" type="Company"><TargetEntity id="4295905460" type="organizationId">Akorn Inc</TargetEntity></SourceEntity><SourceEntity id="19" type="ciIndication"><TargetEntity id="10002091" type="MEDDRA"/><TargetEntity id="D000758" type="MeSH"/><TargetEntity id="-564538434" type="omicsDisease"/><TargetEntity id="23" type="siCondition"/></SourceEntity><SourceEntity id="239" type="ciIndication"><TargetEntity id="10015916" type="MEDDRA"/><TargetEntity id="D005128" type="MeSH"/><TargetEntity id="-2056365523" type="omicsDisease"/><TargetEntity id="754" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Anesthesia - US - Oct-2008</FirstLaunched><FirstLaunched>Ocular disease - US - Oct-2008</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="19">Anesthesia</Indication><Indication id="239">Ocular disease</Indication></IndicationsPrimary><ActionsSecondary><Action id="1667">Anesthetic</Action><Action id="59620">Unspecified drug target</Action></ActionsSecondary><Technologies><Technology id="620">Ophthalmic formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="772">Ophthalmic gel formulation</Technology></Technologies><EphmraCodes><Ephmra><Code>N1</Code><Name>ANAESTHETICS</Name></Ephmra></EphmraCodes><LastModificationDate>2018-11-07T05:35:25.000Z</LastModificationDate><ChangeDateLast>2018-09-11T00:00:00.000Z</ChangeDateLast><AddedDate>2005-08-16T15:19:23.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="28817" linkType="Company"&gt;Akorn&lt;/ulink&gt; has developed and launched AK-1015 (Akten), a gel formulation of the local anesthetic agent &lt;ulink linkID="44403" linkType="Drug"&gt;lidocaine&lt;/ulink&gt; for use as an ocular anesthetic in ophthalmic surgery or office-based procedures  [&lt;ulink linkID="681383" linkType="Reference"&gt;681383&lt;/ulink&gt;], [&lt;ulink linkID="949819" linkType="Reference"&gt;949819&lt;/ulink&gt;]. The drug was launched in the US in October 2008 [&lt;ulink linkID="953532" linkType="Reference"&gt;953532&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In August 2006, the company planned to file an NDA in 2007 and to launch the drug in 2008 [&lt;ulink linkID="681383" linkType="Reference"&gt;681383&lt;/ulink&gt;]; In April 2007, the company finalized the structure of the NDA submission in a  pre-NDA meeting with the FDA [&lt;ulink linkID="791686" linkType="Reference"&gt;791686&lt;/ulink&gt;], [&lt;ulink linkID="810053" linkType="Reference"&gt;810053&lt;/ulink&gt;].  In May  2007, Akorn   anticipated filing the NDA in the second quarter of 2007 [&lt;ulink linkID="791686" linkType="Reference"&gt;791686&lt;/ulink&gt;]. Akorn filed an NDA in June 2007 [&lt;ulink linkID="810053" linkType="Reference"&gt;810053&lt;/ulink&gt;]. In June 2008, the FDA issued an approvable letter identifying minor CMC deficiencies. At that time, Akorn planned to respond to the agency within 10 days [&lt;ulink linkID="913416" linkType="Reference"&gt;913416&lt;/ulink&gt;]. In October 2008, the product was approved by the FDA. At that time, launch was expected before the end of the month [&lt;ulink linkID="949819" linkType="Reference"&gt;949819&lt;/ulink&gt;]. The drug was launched in the US in October 2008 [&lt;ulink linkID="953532" linkType="Reference"&gt;953532&lt;/ulink&gt;].&lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In August 2006, the FDA approved the company's IND for a pivotal ocular anesthesia trial. The 200-patient, four-arm trial was scheduled to begin later that month [&lt;ulink linkID="681383" linkType="Reference"&gt;681383&lt;/ulink&gt;].  By October 2006, the trial had begun and 104 patients had been enrolled [&lt;ulink linkID="736257" linkType="Reference"&gt;736257&lt;/ulink&gt;]. In January 2007, Akorn reported that the drug met both its primary and secondary  endpoints of  inducing ocular anesthesia and duration of anesthesia, respectively. The randomized, placebo-controlled, multicenter study had enrolled 209 subjects [&lt;ulink linkID="759607" linkType="Reference"&gt;759607&lt;/ulink&gt;].  &lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In June 2007, the market size for AK-1015 was an estimated  six million  procedures annually [&lt;ulink linkID="810053" linkType="Reference"&gt;810053&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By August 2005, Akorn was codeveloping AK-1015 with the New England Eye Center and Retina Vitreous Associates [&lt;ulink linkID="617827" linkType="Reference"&gt;617827&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="28817">Akorn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="239">Ocular disease</Indication><StatusDate>2008-10-15T00:00:00.000Z</StatusDate><Source id="953532" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="28817">Akorn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2008-10-15T00:00:00.000Z</StatusDate><Source id="953532" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="28817">Akorn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="239">Ocular disease</Indication><StatusDate>2005-08-15T00:00:00.000Z</StatusDate><Source id="617827" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28817">Akorn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2006-08-01T00:00:00.000Z</StatusDate><Source id="681383" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28817">Akorn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="239">Ocular disease</Indication><StatusDate>2006-10-30T00:00:00.000Z</StatusDate><Source id="736257" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28817">Akorn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2006-10-30T00:00:00.000Z</StatusDate><Source id="736257" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28817">Akorn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="239">Ocular disease</Indication><StatusDate>2007-06-30T00:00:00.000Z</StatusDate><Source id="810053" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28817">Akorn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="PR" sortOrder="13">Pre-registration</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2007-06-30T00:00:00.000Z</StatusDate><Source id="810053" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28817">Akorn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="19">Anesthesia</Indication><StatusDate>2008-10-08T00:00:00.000Z</StatusDate><Source id="949819" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="28817">Akorn Inc</Company><Country id="US">US</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="239">Ocular disease</Indication><StatusDate>2008-10-08T00:00:00.000Z</StatusDate><Source id="949819" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1040919">Retina Vitreous Associates, P.C.</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="28817">Akorn Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="7">Drug - Development Services</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>CCN(CC)CC(=O)Nc1c(cccc1C)C</Smiles></StructureSmiles><Deals><Deal id="124026" title="Akorn to codevelop AK-1015 with New England Eye Center and Retina Vitreous Associates"/></Deals><PatentFamilies><PatentFamily id="2205123" number="WO-2008014036" title="Aqueous gel formulation and method for inducing topical anesthesia"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Allergan plc" id="1088700"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Akorn Inc" id="28817"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></Drug></drugRecordsOutput>